Table 1.
Correlation of EZH2 expression with clinicopathological status in ovarian cancer patients.
| Clinicopathological status | N | EZH2b | P valuec | |
|---|---|---|---|---|
| High (%) | Low (%) | |||
| GSE9891 | ||||
| Age (year) | 0.883 | |||
| >50 | 232 | 174 (75) | 58 (25) | |
| ≤50 | 50 | 37 (74.0) | 13 (26.0) | |
| Unknowna | 3 | 2 | 1 | |
| FIGO stage | 0.001 | |||
| I | 24 | 12 (50.0) | 12 (50.0) | |
| II | 18 | 12 (66.7) | 6 (33.3) | |
| III | 217 | 175 (80.6) | 42 (19.4) | |
| IV | 22 | 12 (54.5) | 10 (45.5) | |
| Unknowna | 4 | 2 | 2 | |
| Histologic grade | 7.8276e-7 | |||
| G1 | 19 | 5 (26.3) | 14 (73.7) | |
| G2 | 97 | 71 (73.2) | 26 (26.8) | |
| G3 | 164 | 134 (81.7) | 30 (18.3) | |
| Unknowna | 5 | 3 | 2 | |
| Histological type | 0.27 | |||
| Serous | 264 | 195 (73.9) | 69 (26.1) | |
| Endometrioid | 20 | 17 (85.0) | 3 (15.0) | |
| Unknowna | 1 | 1 | 0 | |
| Metastasis | 0.003 | |||
| Yes | 257 | 199 (77.4) | 58 (22.7) | |
| No | 24 | 12 (50.0) | 12 (50.0) | |
| Unknowna | 4 | 2 | 2 | |
| GSE26193 | ||||
| FIGO stage | 0.004 d | |||
| I | 20 | 9 (45.0) | 11 (55.0) | |
| II | 11 | 8 (72.7) | 3 (27.3) | |
| III | 59 | 47 (79.7) | 12 (20.3) | |
| IV | 17 | 14 | 3 | |
| Histological grade | 0.004 | |||
| G1 | 7 | 2 (28.6) | 5 (71.4) | |
| G2 | 33 | 21 (63.6) | 12 (36.4) | |
| G3 | 67 | 55 (82.1) | 12 (17.9) | |
| Histological type | 0.485 | |||
| Serous | 79 | 59 (74.7) | 20 (25.3) | |
| Otherse | 28 | 19 (67.9) | 9 (32.1) | |
| Metastasis | 0.002 | |||
| Yes | 87 | 69 (79.3) | 18 (20.7) | |
| No | 20 | 9 (45.0) | 11 (55.0) | |
| Unknowna | 4 | 2 | 2 | |
| The present study | ||||
| Age (year) | 0.647 | |||
| >50 | 41 | 25 (61.0) | 16 (39.0) | |
| ≤50 | 41 | 27 (65.9) | 14 (34.1) | |
| FIGO stage | 0.002 | |||
| I-II | 22 | 8 (36.4) | 14 (63.6) | |
| III-IV | 60 | 44 (73.3) | 16 (26.7) | |
| Histological type f | 0.152 | |||
| Type I | 20 | 10 (50.0) | 10 (50.0) | |
| Type II | 62 | 42 (67.7) | 20 (32.3) | |
aStatistics did not include the Unknown group.
bCut-off point for EZH2 mRNA from databases was determined by ROC curve. Cut-off point for EZH2 protein was defined as tissues whose positive staining nuclear percentage were greater than 25%.
cChi-square test.
dFisher’s exact tests.
eInclude mucinous, endometrioid, clear cells, carcinosarcome and brenner tumor.
fType I includes low-grade serous, endometrioid, mucinous, and clear cell tumors; Type II includes high-grade serous tumor.
Boldface type indicates significant values.